

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Weiner, et al.
App. No : 10/759,561
Filed : January 15, 2004
For : SELECTIVE SEROTONIN 2A/2C
RECEPTOR INVERSE AGONISTS AS
THERAPEUTICS FOR
NEURODEGENERATIVE DISEASES
Examiner : Williams, Leonard M.
Art Unit : 1617

CERTIFICATE OF EFS WEB
TRANSMISSION

I hereby certify that this correspondence, and
any other attachment noted on the automated
Acknowledgement Receipt, is being transmitted
from within the Pacific Time zone to the
Commissioner for Patents via the EFS Web
server on:

6-20-08

(Date)



Ryan E. Melnick; Reg. No. 58,621

REQUEST TO CORRECT INVENTORSHIP

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication is a request to correct the original naming of inventors under 37 C.F.R. § 1.48 as set forth in the original declaration filed on June 21, 2004 in the above-named application.

Please add the following persons as inventors of this application.

Carl-Magnus A. Andersson
Ferievägen 3
SE-245 64 Hjärrup, Sweden

and

Allan K. Uldam
Skotteparken 172
2750 Ballerup, Denmark

Attached is the Statement of Carl-Magnus A. Andersson and Allan K. Uldam under 37 C.F.R. § 1.48(a)(2) that the error in inventorship occurred without deceptive intention on his part,

Appl. No. : 10/759,561
Filed : January 15, 2004

a new declaration by the actual inventors pursuant to 37 C.F.R. § 1.48(a)(3), and the written consent of the assignee pursuant to 37 C.F.R. § 1.48(a)(5).

The required fee payment (37 C.F.R. § 1.1.17(i)) is paid herewith. Please charge any additional fees to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6-20-08

By: Ryan E. Melnick
Ryan E. Melnick
Registration No. 58,621
Attorney of Record
Customer Number 20,995
(619) 235-8550

4545253:sad
111507

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Weiner, et al.
Appl. No.	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Leonard M. Williams
Group Art Unit	:	1617

CONSENT OF ASSIGNEE UNDER 37 U.S.C., § 1.48(a)(5) TO ADD INVENTORS

The undersigned is empowered to act on behalf of the Assignee of the above-named application, Acadia Pharmaceuticals Inc. ("Assignee"). The Assignee represents that it is the 100% owner by assignment of the above-referenced application by virtue of the assignments recorded at Reel Nos. 015548/019218 and Frame Nos. 0274/0633 by the Assignment Branch of the Patent and Trademark Office. The Assignee hereby consents to the addition of the following inventors:

Carl-Magnus A. Andersson
Ferievägen 3
SE-245 64 Hjärrup, Sweden

and

Allan K. Uldam
Skotteparken 172
2750 Ballerup, Denmark

Dated: 1/18/08

By: Uli Hacksell
Print Name


Signed

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Weiner, et al.
Appl. No.	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Leonard M. Williams
Group Art Unit	:	1617

STATEMENT OF CARL-MAGNUS A. ANDERSSON UNDER 37 C.F.R. § 1.48(a)(2)

Mailstop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

I, Carl-Magnus A. Andersson, am an inventor of subject matter claimed in the above-referenced patent application. The failure to include my name as an inventor was an error that occurred without any deceptive intent on my part.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardized the validity of the application or patent issuing therefrom.

Dated: 1/18/08

Respectfully submitted,

By: 
Carl-Magnus A. Andersson

4546082:sad
111507

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Weiner, et al.
Appl. No.	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Leonard M. Williams
Group Art Unit	:	1617

STATEMENT OF ALLAN K. ULDAM UNDER 37 C.F.R. § 1.48(a)(2)

Mailstop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Allan K. Uldam, am an inventor of subject matter claimed in the above-referenced patent application. The failure to include my name as an inventor was an error that occurred without any deceptive intent on my part.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardized the validity of the application or patent issuing therefrom.

Respectfully submitted,

Dated: 18-DEC-2007

By: 
Allan K. Uldam

4546094:sad
111507